IP Library Granted Patent US 9,370,325
Granted Patent B2
US 9,370,325 · App. 14/714,691 · Granted Jun 21, 2016

Hemoglobin display and patient treatment

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,370,325
App. No.
14/714,691
Granted
Jun 21, 2016
Kind
B2
Abstract

The present disclosure describes embodiments of a patient monitoring system and methods that include the measure and display of hemoglobin statistics. In an embodiment, total hemoglobin trending is displayed over a period of time. Statistics can include frequency domain analysis, which may be unique for each patient monitored. The total hemoglobin trending and/or statistics can further be used to help control the treatment of a patient, such as being used to control IV administration.

Claims (37)

1. A patient monitoring system comprising:

a noninvasive sensor for emitting energy into a patient measurement site of a patient and detecting the energy attenuated by the patient measurement site;

a memory buffer; and

a hardware processor configured to determine a first plurality of total hemoglobin readings over a first time period using the attenuated energy detected by the sensor and store the first plurality of total hemoglobin readings in the memory buffer,

wherein said hardware processor is further configured to frequency transform the first plurality of total hemoglobin readings stored in the memory buffer,

determine frequency data from the first plurality of total hemoglobin readings; and

determine a hemoglobin characteristic of the patient from the frequency data.

2. The patient monitoring system of claim 1 , wherein the hemoglobin characteristic comprises an abnormality.

3. The patient monitoring system of claim 2 , wherein the abnormality comprises sickle cell anemia.

4. The patient monitoring system of claim 2 , wherein the abnormality comprises Thalasemia.

5. The patient monitoring system of claim 2 , wherein the abnormality comprises abnormal spleen function.

6. The patient monitoring system of claim 1 , wherein the hemoglobin characteristic comprises a type of hemoglobin.

7. A patient monitoring system comprising:

a hardware processor configured to:

determine a first plurality of total hemoglobin readings over a first time period using the attenuated energy detected by a noninvasive sensor attached to a patient;

store the first plurality of total hemoglobin readings in a memory buffer;

transform the first plurality of total hemoglobin readings stored in the memory buffer in a frequency domain; and

determine a hemoglobin characteristic of the patient based on the transformed total hemoglobin readings.

8. The patient monitoring system of claim 7 , wherein the hemoglobin characteristic comprises an abnormality.

9. The patient monitoring system of claim 8 , wherein the abnormality comprises sickle cell anemia.

10. The patient monitoring system of claim 8 , wherein the abnormality comprises Thalasemia.

11. The patient monitoring system of claim 8 , wherein the abnormality comprises abnormal spleen function.

12. The patient monitoring system of claim 8 , wherein the hemoglobin characteristic comprises a type of hemoglobin.

13. The patient monitoring method of claim 7 , wherein the hardware processor is further configured to control a treatment unit based on the determined hemoglobin characteristic.

14. A patient monitoring method comprising:

emitting energy into a patient measurement site of a patient;

detecting the energy attenuated by the patient measurement site;

determining a first plurality of total hemoglobin readings over a first time period using the attenuated energy detected;

storing the first plurality of total hemoglobin readings in a memory buffer;

transforming the first plurality of total hemoglobin readings stored in the memory buffer in a frequency domain; and

determining a hemoglobin characteristic of the patient based on the transformed total hemoglobin readings.

15. The patient monitoring method of claim 14 , wherein the hemoglobin characteristic comprises an abnormality.

16. The patient monitoring method of claim 15 , wherein the abnormality comprises sickle cell anemia.

17. The patient monitoring method of claim 15 , wherein the abnormality comprises Thalasemia.

18. The patient monitoring method of claim 15 , wherein the abnormality comprises abnormal spleen function.

19. The patient monitoring method of claim 15 , wherein the hemoglobin characteristic comprises a type of hemoglobin.

20. The patient monitoring method of claim 14 , further comprising controlling a treatment unit based on the determined hemoglobin characteristic.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 19, 2016
From: AL-ALI, AMMAR; KIANI, MASSI JOE E.; O'REILLY, MICHAEL
To: MASIMO CORPORATION
Reel/Frame 038652/0942 →